We are live on ! Find out more
XTLB

XTL Biopharmaceuticals
XTLB

4 hedge funds and large institutions have $266K invested in XTL Biopharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

2% more capital invested

Capital invested by funds: $261K → $266K (+$4.7K)

0% more funds holding

Funds holding: 4 → 4 (0)

0.02% less ownership

Funds ownership: 2.59% → 2.57% (-0.02%)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
4
Holders Change
–
Holders Change %
0%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$1.39K
2
UBS Group
UBS Group
Switzerland
-$795

XTLB Hedge Fund Activity: Q3 2025 in Review

4 of the 7,645 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q3 2025, worth a combined $266K — up 1.8% from $261K a quarter earlier.

Fund positioning in XTLB was balanced in Q3 2025: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 2 trimmed.

The largest seller was Morgan Stanley, cutting an estimated $1.39K.

  • 4 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q3 2025, unchanged from Q2 2025.
  • Funds reported $266K of XTL Biopharmaceuticals stock for Q3 2025, up 1.8% quarter-over-quarter.
  • 0 funds opened new XTL Biopharmaceuticals positions in Q3 2025 and 0 closed out.
  • The largest XTL Biopharmaceuticals seller in Q3 2025 was Morgan Stanley, an estimated $1.39K sold.

Based on aggregated 13F filings for Q3 2025.